[go: up one dir, main page]

RU2018137032A3 - - Google Patents

Download PDF

Info

Publication number
RU2018137032A3
RU2018137032A3 RU2018137032A RU2018137032A RU2018137032A3 RU 2018137032 A3 RU2018137032 A3 RU 2018137032A3 RU 2018137032 A RU2018137032 A RU 2018137032A RU 2018137032 A RU2018137032 A RU 2018137032A RU 2018137032 A3 RU2018137032 A3 RU 2018137032A3
Authority
RU
Russia
Application number
RU2018137032A
Other languages
Russian (ru)
Other versions
RU2018137032A (en
RU2760733C2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018137032A publication Critical patent/RU2018137032A/en
Publication of RU2018137032A3 publication Critical patent/RU2018137032A3/ru
Application granted granted Critical
Publication of RU2760733C2 publication Critical patent/RU2760733C2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2018137032A 2016-03-25 2017-03-20 Pyrimidines and their options, and their application RU2760733C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
US62/313,334 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (3)

Publication Number Publication Date
RU2018137032A RU2018137032A (en) 2020-04-27
RU2018137032A3 true RU2018137032A3 (en) 2020-05-22
RU2760733C2 RU2760733C2 (en) 2021-11-30

Family

ID=59900805

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018137032A RU2760733C2 (en) 2016-03-25 2017-03-20 Pyrimidines and their options, and their application

Country Status (11)

Country Link
US (2) US10662162B2 (en)
EP (1) EP3433258B1 (en)
JP (1) JP6902045B2 (en)
KR (1) KR102377805B1 (en)
CN (1) CN108779119B (en)
AU (1) AU2017237929B2 (en)
CA (1) CA3018180C (en)
MA (1) MA44489A (en)
MX (1) MX384368B (en)
RU (1) RU2760733C2 (en)
WO (1) WO2017165255A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102489454B1 (en) 2016-03-14 2023-01-17 애퍼런트 파마슈티컬스 인크. Pyrimidines and variants thereof, and uses therefor
EP3433258B1 (en) 2016-03-25 2023-07-19 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
KR102454635B1 (en) 2016-12-19 2022-10-17 노파르티스 아게 Novel picolinic acid derivatives and their use as intermediates
CA3046027A1 (en) * 2016-12-20 2018-06-28 Prabha Ibrahim Crystalline salts and polymorphs of a p2x3 antagonist
ES2980935T3 (en) * 2017-11-01 2024-10-03 Beijing Tide Pharmaceutical Co Ltd P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising it and its use
CN107778255B (en) * 2017-11-16 2019-10-25 山东大学 A kind of diarylpyrimidine HIV-1 reverse transcriptase inhibitor and its preparation method and application
JP7663508B2 (en) * 2019-04-30 2025-04-16 ベイジン タイド ファーマシューティカル カンパニー リミテッド Methods of Treating Endometriotic Pain by Using Diaminopyrimidine Compounds
SG11202111877TA (en) * 2019-04-30 2021-11-29 Beijing Tide Pharmaceutical Co Ltd Method for treating cough by using diaminopyrimidine compound
SG11202111907UA (en) 2019-04-30 2021-11-29 Beijing Tide Pharmaceutical Co Ltd Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
US20220332714A1 (en) * 2019-06-06 2022-10-20 Beijing Tide Pharmaceutical Co., Ltd. P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof
CN120058573A (en) * 2025-04-29 2025-05-30 潍坊学院 Synthesis method of 1-tribromomethylsulfonyl naphthalene and derivative thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
WO2000059893A1 (en) * 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
EP1345927B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PL1725540T3 (en) * 2004-03-05 2013-02-28 Hoffmann La Roche Diaminopyrimidines as p2x3 and p2x2/3 antagonists
BRPI0615613A2 (en) * 2005-09-01 2009-05-19 Hoffmann La Roche diaminopyrimidines as p2x3 and p3x2 / 3 modulators
JP4850914B2 (en) * 2005-09-01 2012-01-11 エフ.ホフマン−ラ ロシュ アーゲー Diaminopyrimidines as P2X3 and P2X2 / 3 modulators
EP1924564B1 (en) * 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
JP4850913B2 (en) * 2005-09-01 2012-01-11 エフ.ホフマン−ラ ロシュ アーゲー Diaminopyridines as P2X3 and P2X2 / 3 regulators
JP5128603B2 (en) * 2006-10-04 2013-01-23 エフ.ホフマン−ラ ロシュ アーゲー Method for the synthesis of phenoxydiaminopyrimidine derivatives
WO2008104472A1 (en) 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
CA2699631A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone compounds and p2x7 receptor inhibitors
GB2471713A (en) * 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
TWI637949B (en) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 Aminotriazine derivative and pharmaceutical composition comprising the same
SG11201601145RA (en) * 2013-08-23 2016-03-30 Afferent Pharmaceuticals Inc Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
EP3981406A1 (en) * 2014-07-03 2022-04-13 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
KR102489454B1 (en) * 2016-03-14 2023-01-17 애퍼런트 파마슈티컬스 인크. Pyrimidines and variants thereof, and uses therefor
EP3433258B1 (en) 2016-03-25 2023-07-19 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor

Also Published As

Publication number Publication date
EP3433258A1 (en) 2019-01-30
RU2018137032A (en) 2020-04-27
KR20180128015A (en) 2018-11-30
US11230532B2 (en) 2022-01-25
MX2018011622A (en) 2019-03-28
KR102377805B1 (en) 2022-03-22
CN108779119A (en) 2018-11-09
AU2017237929A1 (en) 2018-09-13
WO2017165255A1 (en) 2017-09-28
US10662162B2 (en) 2020-05-26
MA44489A (en) 2019-01-30
JP2019510025A (en) 2019-04-11
US20190055202A1 (en) 2019-02-21
BR112018069105A2 (en) 2019-01-29
CA3018180A1 (en) 2017-09-28
RU2760733C2 (en) 2021-11-30
AU2017237929B2 (en) 2021-04-15
MX384368B (en) 2025-03-14
EP3433258B1 (en) 2023-07-19
JP6902045B2 (en) 2021-07-14
CA3018180C (en) 2024-02-20
CN108779119B (en) 2022-02-08
US20200239421A1 (en) 2020-07-30
EP3433258A4 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
BR122021017409A2 (en)
BR112018003417A2 (en)
BR112019002665A2 (en)
RU2018137032A3 (en)
BR112019009366A2 (en)
BR112019009203A2 (en)
BR202016030146U2 (en)
CN303537604S (en)
CN303537899S (en)
CN303535879S (en)
CN303535882S (en)
CN303536131S (en)
CN303536207S (en)
CN303536214S (en)
CN303536235S (en)
CN303536441S (en)
CN303536492S (en)
CN303536497S (en)
CN303536515S (en)
CN303536550S (en)
CN303536594S (en)
CN303539267S (en)
CN303536867S (en)
CN303537445S (en)
CN303539387S (en)